Noresmea (Norethisterone Acetate, Estradiol)

Norethisterone acetate and estradiol, the active ingredients in Noresmea, are a combined estrogen and progestogen presented as a 1 mg/2 mg oral tablet for oral use. It treats estrogen deficiency and provides hormonal contraception in women of reproductive age.

GNH USA supplies Noresmea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Noresmea is a combined estrogen‑progestogen tablet used in hormone‑related therapeutic pathways.

Hormone replacement therapy in postmenopausal women: alleviates vasomotor symptoms and helps maintain bone density. Contraception in women of reproductive age: suppresses ovulation to prevent pregnancy. Management of menstrual disorders such as dysmenorrhea or irregular bleeding: stabilises the endometrial lining.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of breast tissue. - Headache: transient cranial pain. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional fluctuations. - Spotting: irregular uterine bleeding.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe hypertension: sudden rise in blood pressure. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Allergic reactions: rash, swelling, or anaphylaxis. - Visual disturbances: sudden vision loss or blurred sight.

Before prescribing Noresmea, consider the following precautions.

Assess cardiovascular risk: evaluate history of thrombosis or clotting disorders. Screen for liver disease: monitor hepatic function tests. Consider bone health: ensure adequate calcium and vitamin D intake. Avoid in known estrogen‑dependent tumors: contraindicated in breast or endometrial cancer. Pregnancy testing: confirm patient is not pregnant before initiation. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Noresmea may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine): reduce hormonal efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase hormone concentrations. - Anticoagulants (e.g., warfarin): elevate risk of thrombotic events.

Moderate Interactions (Monitor Closely): - Antihypertensives: may require dose adjustment. - Selective serotonin reuptake inhibitors: may heighten mood‑related side effects. - St. John’s wort: may lower contraceptive effectiveness.